信达生物引入GlycoT的定点偶联ADC技术

药时代
Yesterday

2025年6月13日,信达生物与GlycoT Therapeutics宣布达成一项战略合作。根据协议,信达生物获得了GlycoT公司自主研发的定点偶联ADC(抗体-药物偶联物)技术的全球非排他性使用权。尽管双方未披露具体财务条款,但此次合作的战略意义不言而喻。糖基定点偶联抗体偶联药物(ADC)是一种新兴的精准癌症治疗手段,通过将细胞毒性药物与特异性单克隆抗体相结合,实现对肿瘤细胞的精确靶向和高效...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10